Related Experiment Video
Updated: May 5, 2026
A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
Published on: May 3, 2021
Design, synthesis and biological evaluation of ezrin inhibitors targeting metastatic osteosarcoma
Mikell Paige1, George Kosturko2, Güllay Bulut3
1George Mason University, Department of Chemistry and Biochemistry, 10900 University Blvd, MS 1A9, Manassas, VA 20110, USA; Georgetown University Medical Center, Center for Drug Discovery, 3970 Reservoir Road, NW, The Research Building, Room EP07, Washington, DC 20057, USA.
Abstract:
Respiratory failure due to pulmonary metastasis is the major cause of death for patients with osteosarcoma. However, the molecular basis for metastasis of osteosarcoma is poorly understood. Recently, ezrin, a member of the ERM family of proteins, has been associated with osteosarcoma metastasis to the lungs. The small molecule NSC 668394 was identified to bind to ezrin, inhibit in vitro and in vivo cell migration, invasion, and metastatic colony survival. Reported herein are the design and synthesis of analogues of NSC 668394, and subsequent functional ezrin inhibition studies. The binding affinity was characterized by surface plasmon resonance technique. Cell migration and invasion activity was determined by electrical cell impedance methodology. Optimization of a series of heterocyclic-dione analogues led to the discovery of compounds 21k and 21m as potential novel antimetastatic agents.
Insights
Researchers explored novel compounds to combat osteosarcoma metastasis. They identified two new agents, 21k and 21m, that inhibit ezrin protein, showing promise in preventing cancer spread.
Area of Science:
- Oncology
- Molecular Biology
- Medicinal Chemistry
Background:
- Pulmonary metastasis is a primary cause of death in osteosarcoma patients.
- The molecular mechanisms driving osteosarcoma metastasis remain largely unknown.
- Ezrin, an ERM protein, has been implicated in osteosarcoma lung metastasis.
Purpose of the Study:
- To design and synthesize novel analogues of the ezrin-binding molecule NSC 668394.
- To evaluate the antimetastatic potential of these analogues.
- To identify new therapeutic agents for osteosarcoma.
Main Methods:
- Synthesis of heterocyclic-dione analogues of NSC 668394.
- Surface plasmon resonance to characterize binding affinity to ezrin.
- Electrical cell impedance methodology to assess cell migration and invasion.
Main Results:
- Several analogues were synthesized and tested for ezrin inhibition.
- Compounds 21k and 21m demonstrated significant inhibition of ezrin.
- These compounds effectively reduced cell migration and invasion in vitro.
Conclusions:
- Ezrin is a viable therapeutic target for osteosarcoma metastasis.
- Compounds 21k and 21m represent promising novel antimetastatic agents.
- Further investigation into these compounds could lead to new osteosarcoma treatments.
